Poseida Corp (PSTX) Cash Funds per Single Share

Symbol and logo of brand Poseida Corp (PSTX)

Poseida Therapeutics (PSTX) maintains a high reputation as a creator of precise non-viral gene modification systems for myeloma therapy. The issuer's revenues are based on partnerships to develop innovative treatments for oncology and hematology. Financial stability is supported by regular payments from pharma behemoths. The trend in free cash flow per share demonstrates the liquidity level, with the current mark equal to 2.35.

PSTX Poseida Therapeutics Inc: Cash per Single Share in the range 07/04/2022 - 01/18/2025

Comprehensive metric breakdowns and analytics for Poseida Therapeutics, Inc. (PSTX)

- market price and analyst price targets:
- cash and cash flow data:
Summary company analysis:PSTX (Poseida Corp)
Finished products of poseida.com

The assessment of Poseida Therapeutics (PSTX) resilience to market downturns depends on the available volume of liquidity. Developing gene therapies based on piggyBac and Cas-CLOVER platforms requires colossal capital expenditures. The cash per share trend captures the proportion of cash reserves attributable to a single security. Daily monitoring of this metric allows for the real-time assessment of inflows from grants or partnerships with Roche. The upward trend of this line confirms the business's financial autonomy.